Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2015 07:00 ET | Source: Revance Therapeutics, Inc

Revance Reports Positive 6-Month Duration in BELMONT Study

– 6-month duration of effect is statistically significant compared to BOTOX® Cosmetic – – All dose levels of RT002 achieved highly statistically significant,...
September 29, 2015 16:02 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia

NEWARK, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
September 28, 2015 16:02 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines

NEWARK, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
September 09, 2015 16:02 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis

NEWARK, Calif., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
August 06, 2015 16:02 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Releases Second Quarter 2015 Results

NEWARK, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
July 23, 2015 16:02 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics to Release Second Quarter 2015 Financial Results Thursday, August 6, 2015

NEWARK, Calif., July 23, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
July 02, 2015 16:06 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.

NEWARK, Calif., July 2, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
June 03, 2015 07:30 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate

NEWARK, Calif., June 3, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
May 21, 2015 08:30 ET | Source: Revance Therapeutics, Inc

Revance to Participate in Upcoming Investor Conferences

NEWARK, Calif., May 21, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
May 13, 2015 16:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Releases First Quarter 2015 Financial Results

NEWARK, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...